Zhihao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhihao Xu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Lingyun Lou
Department of Respiratory and Critical Care Medicine Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu China
3 shared publicationsXiu Huang
Department of Respiratory and Critical Care Medicine Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu China
3 shared publicationsHaibo Gu
Department of Respiratory and Critical Care Medicine Fourth Affiliated Hospital of Zhejiang University School of Medicine Yiwu China
2 shared publicationsQianru Wei
Department of Respiratory Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China
2 shared publicationsSonghua Hu
Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, 322000, People’s Republic of China
2 shared publications- Wenjun Guan
Department of Respiratory Medicine, the Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu 322000, China
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Breakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension
Pulmonary hypertension (PH) is a rare and life-threatening vascular disorder characterized by complex and multifactorial pathogenesis. Emerging evidence indicates that pulmonary vascular remodeling is driven by coordinated abnormalities in genetic susceptibility, epigenetic regulation, metabolic reprogramming, immune-inflammatory crosstalk, and DNA damage repair. Recent advances in multi-omics profiling, single-cell technologies, and high-resolution imaging have substantially improved the understanding of PH pathobiology and disease heterogeneity. Current therapeutic strategies mainly target the three classical vasoactive pathways to alleviate vasoconstriction and improve hemodynamics. Notably, (bone morphogenetic protein) BMP/transforming growth factor‑β1 (TGF-β) pathway-targeted therapy, represented by sotatercept, has initiated a new era of disease-modifying treatment aimed at reversing pulmonary vascular remodeling. In addition, emerging therapies targeting immune, hormonal, and metabolic pathways have demonstrated promising therapeutic potential. Despite significant progress in both basic and clinical research, major challenges remain, including precise phenotypic stratification, long-term therapeutic safety, and individualized treatment optimization. This review summarizes recent advances in the molecular mechanisms and comprehensive management of PH and highlights future directions for translational research and precision medicine.
- 14 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Open AccessBreakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension
Pulmonary hypertension (PH) is a rare and life-threatening vascular disorder characterized by complex and multifactorial pathogenesis. Emerging evidence indicates that pulmonary vascular remodeling is driven by coordinated abnormalities in genetic susceptibility, epigenetic regulation, metabolic reprogramming, immune-inflammatory crosstalk, and DNA damage repair. Recent advances in multi-omics profiling, single-cell technologies, and high-resolution imaging have substantially improved the understanding of PH pathobiology and disease heterogeneity. Current therapeutic strategies mainly target the three classical vasoactive pathways to alleviate vasoconstriction and improve hemodynamics. Notably, (bone morphogenetic protein) BMP/transforming growth factor‑β1 (TGF-β) pathway-targeted therapy, represented by sotatercept, has initiated a new era of disease-modifying treatment aimed at reversing pulmonary vascular remodeling. In addition, emerging therapies targeting immune, hormonal, and metabolic pathways have demonstrated promising therapeutic potential. Despite significant progress in both basic and clinical research, major challenges remain, including precise phenotypic stratification, long-term therapeutic safety, and individualized treatment optimization. This review summarizes recent advances in the molecular mechanisms and comprehensive management of PH and highlights future directions for translational research and precision medicine.
- Open Access
- 31 March 2026
- Published by MDPI AG in Preprints.org
Artiffcial Intelligence in Post-Translational Modiffcation Site Prediction: Progress and Future Perspectives
Post-translational modiffcations (PTMs) are pivotal in modulating protein function and cellular processes. However, experimental identiffcation of PTM sites remains costly and labor-intensive. Recent advances in artiffcial intelligence (AI) have empowered accurate and scalable in silico PTM site prediction from largescale proteomic data. In this review, we provide a comprehensive and up-to-date overview of AI-driven PTM site prediction across more than ten PTM classes, covering single-PTM site prediction, multiple-PTM site prediction, inter-site crosstalk prediction, and functional prediction of modiffcation sites. We systematically analyze and compare key AI frameworks, from conventional machine learning to deep learning, and summarize representative tools. We also identify key challenges and propose future directions for improvement. To foster application and ongoing progress, we provide practical guidelines for method selection and have established a dedicated website, which serves as a community benchmarking resource for the development of PTM site prediction tools. This website will be regularly updated with emerging prediction tools. By integrating comprehensive literature analysis with a dynamic online resource, we aim to provide a robust cornerstone for understanding current capabilities and guiding the future development of PTM site prediction tools, thereby promoting the integration of AI into practical biomedical research applications.
- 31 March 2026
- Published by MDPI AG in Preprints.org
Open AccessArtiffcial Intelligence in Post-Translational Modiffcation Site Prediction: Progress and Future Perspectives
Post-translational modiffcations (PTMs) are pivotal in modulating protein function and cellular processes. However, experimental identiffcation of PTM sites remains costly and labor-intensive. Recent advances in artiffcial intelligence (AI) have empowered accurate and scalable in silico PTM site prediction from largescale proteomic data. In this review, we provide a comprehensive and up-to-date overview of AI-driven PTM site prediction across more than ten PTM classes, covering single-PTM site prediction, multiple-PTM site prediction, inter-site crosstalk prediction, and functional prediction of modiffcation sites. We systematically analyze and compare key AI frameworks, from conventional machine learning to deep learning, and summarize representative tools. We also identify key challenges and propose future directions for improvement. To foster application and ongoing progress, we provide practical guidelines for method selection and have established a dedicated website, which serves as a community benchmarking resource for the development of PTM site prediction tools. This website will be regularly updated with emerging prediction tools. By integrating comprehensive literature analysis with a dynamic online resource, we aim to provide a robust cornerstone for understanding current capabilities and guiding the future development of PTM site prediction tools, thereby promoting the integration of AI into practical biomedical research applications.
- Open Access
- 17 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1049
Genomic insights into Bordetella pertussis evolution and macrolide resistance in Yiwu, China
Pertussis, caused by Bordetella pertussis, remains a significant public health concern despite widespread vaccination. Recent increases in macrolide-resistant strains present additional challenges for treatment and control. Yiwu, China—a highly mobile and international city—offers a unique setting to study the genomic evolution and antimicrobial resistance of B. pertussis. In this study, 63 clinical isolates from Yiwu underwent whole-genome sequencing. Over 90% of isolates showed high resistance to macrolides. Genome sizes ranged from 3.53 to 4.15 Mb, with high GC content (67.69–67.80%) and variable repeat rates. Phylogenetic analysis, incorporating 14 international strains, revealed two distinct clades and lineage-specific variations in key vaccine antigen genes, indicating multiple origins and localized evolution. A comparative analysis between resistant and sensitive isolates identified an A2037G substitution in the 23S rRNA gene strongly associated with macrolide resistance. Additionally, 69 highly divergent genes related to transcriptional regulation, recombination, and membrane function were detected. Notably, two outer membrane efflux protein genes, opmD and oprM, showed nonsynonymous mutations potentially linked to resistance enhancement. The presence of genomic islands, prophages, and antigenic gene variation further underscores the dynamic evolution of B. pertussis in the region. This study highlights the urgent need for alternative therapies and improved vaccines, while also demonstrating the value of continued genomic surveillance. Insights into resistance-associated genes offer new targets for functional studies and may guide future strategies in pertussis control.
- 17 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1049
Open AccessGenomic insights into Bordetella pertussis evolution and macrolide resistance in Yiwu, China
Pertussis, caused by Bordetella pertussis, remains a significant public health concern despite widespread vaccination. Recent increases in macrolide-resistant strains present additional challenges for treatment and control. Yiwu, China—a highly mobile and international city—offers a unique setting to study the genomic evolution and antimicrobial resistance of B. pertussis. In this study, 63 clinical isolates from Yiwu underwent whole-genome sequencing. Over 90% of isolates showed high resistance to macrolides. Genome sizes ranged from 3.53 to 4.15 Mb, with high GC content (67.69–67.80%) and variable repeat rates. Phylogenetic analysis, incorporating 14 international strains, revealed two distinct clades and lineage-specific variations in key vaccine antigen genes, indicating multiple origins and localized evolution. A comparative analysis between resistant and sensitive isolates identified an A2037G substitution in the 23S rRNA gene strongly associated with macrolide resistance. Additionally, 69 highly divergent genes related to transcriptional regulation, recombination, and membrane function were detected. Notably, two outer membrane efflux protein genes, opmD and oprM, showed nonsynonymous mutations potentially linked to resistance enhancement. The presence of genomic islands, prophages, and antigenic gene variation further underscores the dynamic evolution of B. pertussis in the region. This study highlights the urgent need for alternative therapies and improved vaccines, while also demonstrating the value of continued genomic surveillance. Insights into resistance-associated genes offer new targets for functional studies and may guide future strategies in pertussis control.
- 3 November 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1765, 466511
From reaction energetics to automated analysis tool auxiliary identification: A self-validating multidimensional liquid chromatography- mass spectrometry framework for characterizing polymerized impurities in carbapenem antibiotics
- 3 November 2025
- Published by Elsevier in Journal of Chromatography A
- Vol. 1765, 466511
From reaction energetics to automated analysis tool auxiliary identification: A self-validating multidimensional liquid chromatography- mass spectrometry framework for characterizing polymerized impurities in carbapenem antibiotics
- Open Access
- 16 October 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1470875
Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a prevalent chronic pulmonary fibrosis disease characterized by alveolar epithelial cell damage, fibroblast proliferation and activation, excessive extracellular matrix deposition, and abnormal epithelial-mesenchymal transition (EMT), resulting in tissue remodeling and irreversible structural distortion. The mortality rate of IPF is very high, with a median survival time of 2–3 years after diagnosis. The exact cause of IPF remains unknown, but increasing evidence supports the central role of epigenetic changes, particularly microRNA (miRNA), in IPF. Approximately 10% of miRNAs in IPF lung tissue exhibit differential expression compared to normal lung tissue. Diverse miRNA phenotypes exert either a pro-fibrotic or anti-fibrotic influence on the progression of IPF. In the context of IPF, epigenetic factors such as DNA methylation and long non-coding RNAs (lncRNAs) regulate differentially expressed miRNAs, which in turn modulate various signaling pathways implicated in this process, including transforming growth factor-β1 (TGF-β1)/Smad, mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways. Therefore, this review presents the epidemiology of IPF, discusses the multifaceted regulatory roles of miRNAs in IPF, and explores the impact of miRNAs on IPF through various pathways, particularly the TGF-β1/Smad pathway and its constituent structures. Consequently, we investigate the potential for targeting miRNAs as a treatment for IPF, thereby contributing to advancements in IPF research.
- 16 October 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1470875
Open AccessRevisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a prevalent chronic pulmonary fibrosis disease characterized by alveolar epithelial cell damage, fibroblast proliferation and activation, excessive extracellular matrix deposition, and abnormal epithelial-mesenchymal transition (EMT), resulting in tissue remodeling and irreversible structural distortion. The mortality rate of IPF is very high, with a median survival time of 2–3 years after diagnosis. The exact cause of IPF remains unknown, but increasing evidence supports the central role of epigenetic changes, particularly microRNA (miRNA), in IPF. Approximately 10% of miRNAs in IPF lung tissue exhibit differential expression compared to normal lung tissue. Diverse miRNA phenotypes exert either a pro-fibrotic or anti-fibrotic influence on the progression of IPF. In the context of IPF, epigenetic factors such as DNA methylation and long non-coding RNAs (lncRNAs) regulate differentially expressed miRNAs, which in turn modulate various signaling pathways implicated in this process, including transforming growth factor-β1 (TGF-β1)/Smad, mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways. Therefore, this review presents the epidemiology of IPF, discusses the multifaceted regulatory roles of miRNAs in IPF, and explores the impact of miRNAs on IPF through various pathways, particularly the TGF-β1/Smad pathway and its constituent structures. Consequently, we investigate the potential for targeting miRNAs as a treatment for IPF, thereby contributing to advancements in IPF research.
- Open Access
- 10 October 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1450038
Notch signaling regulates pulmonary fibrosis
Pulmonary fibrosis is a progressive interstitial lung disease associated with aging. The pathogenesis of pulmonary fibrosis remains unclear, however, alveolar epithelial cell injury, myofibroblast activation, and extracellular matrix (ECM) accumulation are recognized as key contributors. Moreover, recent studies have implicated cellular senescence, endothelial-mesenchymal transition (EndMT), and epigenetic modifications in the pathogenesis of fibrotic diseases. Various signaling pathways regulate pulmonary fibrosis, including the TGF-β, Notch, Wnt, Hedgehog, and mTOR pathways. Among these, the TGF-β pathway is extensively studied, while the Notch pathway has emerged as a recent research focus. The Notch pathway influences the fibrotic process by modulating immune cell differentiation (e.g., macrophages, lymphocytes), inhibiting autophagy, and promoting interstitial transformation. Consequently, inhibiting Notch signaling represents a promising approach to mitigating pulmonary fibrosis. In this review, we discuss the role of Notch signaling pathway in pulmonary fibrosis, aiming to offer insights for future therapeutic investigations.
- 10 October 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1450038
Open AccessNotch signaling regulates pulmonary fibrosis
Pulmonary fibrosis is a progressive interstitial lung disease associated with aging. The pathogenesis of pulmonary fibrosis remains unclear, however, alveolar epithelial cell injury, myofibroblast activation, and extracellular matrix (ECM) accumulation are recognized as key contributors. Moreover, recent studies have implicated cellular senescence, endothelial-mesenchymal transition (EndMT), and epigenetic modifications in the pathogenesis of fibrotic diseases. Various signaling pathways regulate pulmonary fibrosis, including the TGF-β, Notch, Wnt, Hedgehog, and mTOR pathways. Among these, the TGF-β pathway is extensively studied, while the Notch pathway has emerged as a recent research focus. The Notch pathway influences the fibrotic process by modulating immune cell differentiation (e.g., macrophages, lymphocytes), inhibiting autophagy, and promoting interstitial transformation. Consequently, inhibiting Notch signaling represents a promising approach to mitigating pulmonary fibrosis. In this review, we discuss the role of Notch signaling pathway in pulmonary fibrosis, aiming to offer insights for future therapeutic investigations.
- Open Access
- 31 October 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (5) , e0061723
Impact of PpSpi1, a glycosylphosphatidylinositol-anchored cell wall glycoprotein, on cell wall defects of N-glycosylation-engineered Pichia pastoris
In order to produce therapeutic glycoproteins modified with human-like N-glycan structures, much progress has been achieved toward the humanization of N-glycosylation pathways in yeasts. In this study, a Pichia pastoris mutant Glyco4, which has a humanized N-glycosylation pathway and could successfully generate the human-like N-glycans, was carefully characterized. Glyco4 displays a significant growth delay and cell wall defects. Comparative transcriptomics reveals that manipulating the N-glycosylation pathway could notably affect the expression pattern of numerous biological pathways in Glyco4. Among the differentially expressed genes, the down-regulation of Pp SPI1 was proven to be the main cause of the cell wall defects in Glyco4. Deletion of Pp SPI1 in P. pastoris GS115 strain presented growth delay and weaker resistance to cell wall/membrane perturbing agents. PpSpi1 was shown to be a glycosylphosphatidylinositol-anchored cell wall glycoprotein and involved in the formation of the mannoprotein layer on the outer surface of cell wall. Overexpressing Pp SPI1 in Glyco4 could partially recover the cell wall defects and also improve its resistance to cell wall perturbing agents and osmotic stress. Thus, overexpression of PpSpi1 is a useful strategy to facilitate P. pastoris industrial applications in the manufacture of human glycoproteins. IMPORTANCE: Engineering of biological pathways in various microorganisms is a promising direction for biotechnology. Since the existing microbial cells have evolved over a long period of time, any artificial engineering may cause some unexpected and harmful effects on them. Systematically studying and evaluating these engineered strains are very important and necessary. In order to produce therapeutic proteins with human-like N-glycan structures, much progress has been achieved toward the humanization of N-glycosylation pathways in yeasts. The properties of a P. pastoris strain with humanized N-glycosylation machinery were carefully evaluated in this study. Our work has identified a key glycoprotein (PpSpi1) responsible for the poor growth and morphological defects of this glycoengineered strain. Overexpression of PpSpi1 could significantly rescue the growth defect of the glycoengineered P. pastoris and facilitate its future industrial applications.
- 31 October 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (5) , e0061723
Open AccessImpact of PpSpi1, a glycosylphosphatidylinositol-anchored cell wall glycoprotein, on cell wall defects of N-glycosylation-engineered Pichia pastoris
In order to produce therapeutic glycoproteins modified with human-like N-glycan structures, much progress has been achieved toward the humanization of N-glycosylation pathways in yeasts. In this study, a Pichia pastoris mutant Glyco4, which has a humanized N-glycosylation pathway and could successfully generate the human-like N-glycans, was carefully characterized. Glyco4 displays a significant growth delay and cell wall defects. Comparative transcriptomics reveals that manipulating the N-glycosylation pathway could notably affect the expression pattern of numerous biological pathways in Glyco4. Among the differentially expressed genes, the down-regulation of Pp SPI1 was proven to be the main cause of the cell wall defects in Glyco4. Deletion of Pp SPI1 in P. pastoris GS115 strain presented growth delay and weaker resistance to cell wall/membrane perturbing agents. PpSpi1 was shown to be a glycosylphosphatidylinositol-anchored cell wall glycoprotein and involved in the formation of the mannoprotein layer on the outer surface of cell wall. Overexpressing Pp SPI1 in Glyco4 could partially recover the cell wall defects and also improve its resistance to cell wall perturbing agents and osmotic stress. Thus, overexpression of PpSpi1 is a useful strategy to facilitate P. pastoris industrial applications in the manufacture of human glycoproteins. IMPORTANCE: Engineering of biological pathways in various microorganisms is a promising direction for biotechnology. Since the existing microbial cells have evolved over a long period of time, any artificial engineering may cause some unexpected and harmful effects on them. Systematically studying and evaluating these engineered strains are very important and necessary. In order to produce therapeutic proteins with human-like N-glycan structures, much progress has been achieved toward the humanization of N-glycosylation pathways in yeasts. The properties of a P. pastoris strain with humanized N-glycosylation machinery were carefully evaluated in this study. Our work has identified a key glycoprotein (PpSpi1) responsible for the poor growth and morphological defects of this glycoengineered strain. Overexpression of PpSpi1 could significantly rescue the growth defect of the glycoengineered P. pastoris and facilitate its future industrial applications.
- Open Access
- 1 May 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 2911-2919
Asymptomatic Broncholithiasis and Aspergillus Infection: A Case Report and Literature Review
Broncholithiasis coupled with Aspergillus infection is a rare disease of the respiratory system with complex pathogenesis and non-specific clinical manifestations that can be easily confused with other types of infectious diseases of the respiratory system. The lack of pertinent clinical manifestations in patients increases the risk of clinical misdiagnosis, omission, and incorrect treatment plan selection, which can result in permanent lung structural alterations and lung function decompensation and ultimately harm the lung. We report a rare case of asymptomatic broncholithiasis coupled with Aspergillus infection that was treated at our hospital and discuss the pathophysiology, diagnosis, differential diagnosis, and prognostic follow-up course. Furthermore, relevant studies from China and other countries, including this case, were reviewed. We gathered eight reports, summarized their significant diagnoses and treatments for broncholithiasis and broncholithiasis coupled with Aspergillus infection, and discussed their clinical features. Our study may help improve physicians’ awareness of these types of diseases and serve as a resource for future diagnosis and treatment.
- 1 May 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 2911-2919
Open AccessAsymptomatic Broncholithiasis and Aspergillus Infection: A Case Report and Literature Review
Broncholithiasis coupled with Aspergillus infection is a rare disease of the respiratory system with complex pathogenesis and non-specific clinical manifestations that can be easily confused with other types of infectious diseases of the respiratory system. The lack of pertinent clinical manifestations in patients increases the risk of clinical misdiagnosis, omission, and incorrect treatment plan selection, which can result in permanent lung structural alterations and lung function decompensation and ultimately harm the lung. We report a rare case of asymptomatic broncholithiasis coupled with Aspergillus infection that was treated at our hospital and discuss the pathophysiology, diagnosis, differential diagnosis, and prognostic follow-up course. Furthermore, relevant studies from China and other countries, including this case, were reviewed. We gathered eight reports, summarized their significant diagnoses and treatments for broncholithiasis and broncholithiasis coupled with Aspergillus infection, and discussed their clinical features. Our study may help improve physicians’ awareness of these types of diseases and serve as a resource for future diagnosis and treatment.
- Open Access
- 14 February 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1111393
Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic drugs, which can reduce the decline rate of forced vital capacity (FVC) and reduce the risk of acute exacerbation of IPF. However these drugs can not relieve the symptoms associated with IPF, nor improve the overall survival rate of IPF patients. We need to develop new, safe and effective drugs to treat pulmonary fibrosis. Previous studies have shown that cyclic nucleotides participate in the pathway and play an essential role in the process of pulmonary fibrosis. Phosphodiesterase (PDEs) is involved in cyclic nucleotide metabolism, so PDE inhibitors are candidates for pulmonary fibrosis. This paper reviews the research progress of PDE inhibitors related to pulmonary fibrosis, so as to provide ideas for the development of anti-pulmonary fibrosis drugs.
- 14 February 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1111393
Open AccessPerspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) without an identifiable cause. If not treated after diagnosis, the average life expectancy is 3–5 years. Currently approved drugs for the treatment of IPF are Pirfenidone and Nintedanib, as antifibrotic drugs, which can reduce the decline rate of forced vital capacity (FVC) and reduce the risk of acute exacerbation of IPF. However these drugs can not relieve the symptoms associated with IPF, nor improve the overall survival rate of IPF patients. We need to develop new, safe and effective drugs to treat pulmonary fibrosis. Previous studies have shown that cyclic nucleotides participate in the pathway and play an essential role in the process of pulmonary fibrosis. Phosphodiesterase (PDEs) is involved in cyclic nucleotide metabolism, so PDE inhibitors are candidates for pulmonary fibrosis. This paper reviews the research progress of PDE inhibitors related to pulmonary fibrosis, so as to provide ideas for the development of anti-pulmonary fibrosis drugs.
- Open Access
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 848263
Pentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease, and its occurrence and development are mediated by cellular senescence. Drugs targeting senescent cells seem like a promising and efficacious strategy for IPF treatment. Previous studies have illustrated that pentoxifylline (PTX) may play a certain role in inhibiting pulmonary fibrosis and combating cellular senescence. In this study, we demonstrated that PTX administration inhibits pulmonary fibrosis development and cellular senescence in the bleomycin (BLM)-induced IPF mice model. Moreover, the expression levels of fibrosis-related genes and senescence-related genes in mice lung tissue and primary pulmonary fibroblasts illustrated lung fibroblasts’ vital role in these two processes. And the curative effect of PTX was completed mainly by acting on lung fibroblasts. Besides, during the whole treatment, delayed initiation or advanced halt of PTX administration would influence its effectiveness in reducing fibrotic and senescent traits in various degrees, and the latter influenced more. We further determined that a long period of PTX administration could bring noticeable benefits to mice in recovering BLM-induced lung fibrosis and suppressing age-associated cellular senescence. Moreover, it was still effective when PTX administration was used to treat senescent human fibroblasts. Thus, our findings manifested that PTX therapy is an efficient remedy for pulmonary fibrosis by suppressing cellular senescence.
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 848263
Open AccessPentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease, and its occurrence and development are mediated by cellular senescence. Drugs targeting senescent cells seem like a promising and efficacious strategy for IPF treatment. Previous studies have illustrated that pentoxifylline (PTX) may play a certain role in inhibiting pulmonary fibrosis and combating cellular senescence. In this study, we demonstrated that PTX administration inhibits pulmonary fibrosis development and cellular senescence in the bleomycin (BLM)-induced IPF mice model. Moreover, the expression levels of fibrosis-related genes and senescence-related genes in mice lung tissue and primary pulmonary fibroblasts illustrated lung fibroblasts’ vital role in these two processes. And the curative effect of PTX was completed mainly by acting on lung fibroblasts. Besides, during the whole treatment, delayed initiation or advanced halt of PTX administration would influence its effectiveness in reducing fibrotic and senescent traits in various degrees, and the latter influenced more. We further determined that a long period of PTX administration could bring noticeable benefits to mice in recovering BLM-induced lung fibrosis and suppressing age-associated cellular senescence. Moreover, it was still effective when PTX administration was used to treat senescent human fibroblasts. Thus, our findings manifested that PTX therapy is an efficient remedy for pulmonary fibrosis by suppressing cellular senescence.